Tanja Čufer (Author)

Abstract

Letno srečanje ASCO

Keywords

klinična onkologija;imunoterapija;imunska zdravila;novosti;

Data

Language: Slovenian
Year of publishing:
Typology: 1.04 - Professional Article
Organization: OI - Institute of Oncology
UDC: 616-006
COBISS: 2139771 Link will open in a new window
ISSN: 1408-1741
Parent publication: Onkologija
Views: 2865
Downloads: 624
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: ASCO Annual Meeting
Secondary abstract: In the end of May this year, Chicago hosted the traditional annual meeting of oncologists from around the world, which was organised by the American Society of Clinical Oncology (ASCO). Once again, the meeting was attended by more than 30,000 oncologists and other scientists from all over the world. The main topic of this year’s ASCO meeting was definitely cancer immunotherapy. For many years, we have hoped to be able to destroy or at least control cancer cells by stimulating the organism’s own defence. There have been some ups but mostly many downs of immunotherapy. Interferons, interleukins and vaccines have shown a very small level of efficacy, and, even so, only in some types of cancer, alongside a disproportionally high toxicity. A breakthrough was achieved a few years ago, when new immuno-medicines, inhibitors of control switches in T lymphocytes (so-called checkpoint inhibitors), were introduced into clinical trials. In many types of cancer, these medicines led to remissions, which were, most importantly, long-term in patients with remission.
URN: URN:NBN:SI
Pages: str. 30-32
Volume: ǂLetn. ǂ19
Issue: ǂšt. ǂ1
Chronology: jun. 2015
ID: 10917363
Recommended works:
, no subtitle data available
, no subtitle data available
, no subtitle data available
, immune mechanisms of induced protection and tolerance